{
  "issued_date": "2010-08-11", 
  "original_url": "http://www.mhra.gov.uk/Publications/Safetywarnings/MedicalDeviceAlerts/CON090979", 
  "doc_details": {
    "Type": "Medical Device Alert", 
    "Series No": "MDA/2010/064", 
    "Audience": "Healthcare professionals", 
    "Published": "12 August 2010 at 12:00", 
    "Format": "Electronic only", 
    "Size": "A4", 
    "Pages": "5", 
    "Price": "Free", 
    "ISBN/ISSN": "", 
    "Author": "", 
    "Copyright": "Crown"
  }, 
  "_assets": [], 
  "body": "## Device\n\nNovabel\u00ae dermal filler.\n\nManufactured by Merz Pharmaceuticals GmbH.\n\n1x1 ml, Art.-Nr. 40800 and 2x1ml, Art.-Nr. 49021.\n\nAll batches.\n\nNovabel\u00ae is a colourless dermal filler composed of cross-linked alginate. It is supplied in a prefilled, 1 ml, single-use syringe with two sterile 30G \u00bd needles.\n\n## Problem\n\nUse of Novabel\u00ae dermal filler may cause adverse reactions.\n\nMerz Pharmaceuticals GmbH issued a [Field Safety Notice](http://www.mhra.gov.uk/home/ssLINK/CON088238) (dated 23 July 2010), advising practitioners to stop using Novabel\u00ae.\n\nThe manufacturer has received reports of adverse reactions to the filler including redness, bruising, pain, swelling and histologically confirmed granuloma. They have also received reports of nodules and indurations in the infra-orbital area.\n\n## Action  \n  \n  * Do not use Novabel\u00ae dermal filler.  \n  * Return all unused product to Merz Pharma UK Ltd.  \n  * Monitor patients who have received Novabel\u00ae and in particular those who exhibit symptoms linked to the use of Novabel\u00ae.  \n  \n\u00a0  \n  \n  * If you administer Novabel\u00ae:  \n  *     * cease use of the product  \n    * return unused syringes to Merz Pharma UK Ltd.  \n    * following application, patients should have been advised to return and seek treatment in case of progressive adverse reactions including redness, bruising, pain, swelling, nodules, indurations and granuloma  \n    * follow up patients who exhibit residual adverse symptoms (described above) three months after application  \n    * where symptoms persist, consider referring patients to a plastic surgeon for further treatment.  \n  \n\u00a0  \n  \n  * If you are a plastic surgeon:  \n  *     * if a patient presents with symptoms linked to Novabel\u00ae use, consider the need to treat with minocycline or injectable steroids.  \n  \n## Distribution\n\nThis MDA has been distributed to:  \n  \n  * NHS trusts in England (Chief Executives)  \n  * HSC trusts in Northern Ireland (Chief Executives)  \n  * NHS boards in Scotland (Chief Executives)  \n  * NHS boards and trusts in Wales (Chief Executives)  \n  * Primary care trusts in England (Chief Executives)  \n  \nOnward distribution  \nPlease bring this notice to the attention of all who need to know or be aware of it. This may include distribution by:\n\nTrusts to:  \nCAS and SABS (NI) liaison officers for onward distribution to all relevant staff including:  \n  \n  * Clinical governance leads  \n  * Day surgery units  \n  * Dental departments  \n  * Dental nurses  \n  * Dentists  \n  * General surgical units, directors of  \n  * Health and safety managers  \n  * Medical directors  \n  * Nursing executive directors  \n  * Ophthalmic nurses  \n  * Ophthalmologists  \n  * Ophthalmology departments  \n  * Ophthalmology, directors of  \n  * Outpatient clinics  \n  * Outpatient theatre managers  \n  * Outpatient theatre nurses  \n  * Pharmacists  \n  * Purchasing managers  \n  * Supplies managers  \n  \nCare Quality Commission (CQC) (England only) to:  \nThe MHRA considers this information to be important to:  \n  \n  * Clinics  \n  * Hospitals in the independent sector  \n  * Independent treatment centres  \n  * Nursing agencies  \n  * Private medical practitioners  \n  \nHealth Protection Agency to:  \nDirectors for onward distribution to:  \n  \n  * Divisional directors  \n  * Heads of department  \n  * Heads of health, safety and quality  \n  * Health protection nurses  \n  * Risk manager  \n  * Safety officers  \n  \nPrimary care trusts to:  \nCAS liaison officers for onward distribution to all relevant staff including:  \n  \n  * Community dental practices  \n  * Community hospitals  \n  * Community nurses  \n  * Community pharmacists  \n  * Directors of public health  \n  * General dental practitioners  \n  * General practitioners  \n  * NHS walk-in centres  \n  * Practice nurses  \n  \n## Manufacturer Contact\n\nMedical Information Department  \nMerz Pharma UK Ltd  \n260 Centennial Park  \nElstree Hill South  \nElstree  \nHerts  \nWD6 3SR\n\nTel: 020 8236 0000  \nFax: 020 8236 3501\n\nEmail: [medical.information@merz.com](mailto:medical.information@merz.com)\n\n## Feedback\n\nIf you have any comments or feedback on this Medical Device Alert, please email us at: [dts@mhra.gsi.gov.uk](mailto:dts@mhra.gsi.gov.uk)\n\n## England\n\nIf you are in England, please send enquiries about this notice to the MHRA, quoting reference number MDA/2010/064 or 2010/007/023/081/016.\n\nTechnical aspects  \nMiss Feza Haque or Mr Ian Smith  \nMedicines\u00a0and Healthcare products Regulatory Agency  \nMarket Towers  \n1 Nine Elms Lane  \nLondon  \nSW8 5NQ\n\nTel: 020 7084 3066 / 3306  \nFax: 020 7084 3106\n\nEmail: [feza.haque@mhra.gsi.gov.uk](mailto:feza.haque@mhra.gsi.gov.uk)\u00a0and\u00a0[ian.smith@mhra.gsi.gov.uk](mailto:ian.smith@mhra.gsi.gov.uk)\u00a0\n\nClinical aspects  \nDr Nicola Lennard  \nMedicines\u00a0and Healthcare products Regulatory Agency  \nMarket Towers  \n1 Nine Elms Lane  \nLondon  \nSW8 5NQ\n\nTel: 020 7084 3126  \nFax: 020 7084 3111\n\nEmail: [nicola.lennard@mhra.gsi.gov.uk](mailto:nicola.lennard@mhra.gsi.gov.uk)\u00a0\n\nHow to report adverse incidents  \nPlease report via our website: [Reporting adverse incidents involving medical devices](http://www.mhra.gov.uk/Safetyinformation/Reportingsafetyproblems/index.htm).  \nFurther information about CAS can be found on the [Central Alerting System website](https://www.cas.dh.gov.uk/Home.aspx) (external link).\n\n## Northern Ireland\n\nAlerts in Northern Ireland will continue to be distributed via the NI SABS system.\n\nEnquiries and adverse incident reports in Northern Ireland should be addressed to:  \nNorthern Ireland Adverse Incident Centre  \nHealth Estates Investment Group  \nRoom 17  \nAnnex 6  \nCastle Buildings  \nStormont Estate  \nDundonald  \nBT4 3SQ\n\nTel: 02890 523 704  \nFax: 02890 523 900\n\nEmail: [NIAIC@dhsspsni.gov.uk](mailto:NIAIC@dhsspsni.gov.uk)\n\n[Northern Ireland Adverse Incident Centre (NIAIC)](http://www.dhsspsni.gov.uk/index/hea/niaic.htm) (external link)\n\nHow to report adverse incidents in Northern Ireland  \nPlease report directly to NIAIC, further information can be found on the [NIAIC website](http://www.dhsspsni.gov.uk/niaic) (external link).  \nFurther information about SABS can be found on the [SABS website](http://sabs.dhsspsni.gov.uk/NISABS/default.aspx?CATID=3) (external link).\n\n## Scotland\n\nEnquiries and adverse incident reports in Scotland should be addressed to:\n\nIncident Reporting and Investigation Centre  \nHealth Facilities Scotland  \nNHS National Services Scotland  \nGyle Square  \n1 South Gyle Crescent  \nEdinburgh  \nEH12 9EB\n\nTel: 0131 275 7575  \nFax: 0131 314 0722\n\nEmail: [nss.iric@nhs.net](mailto:nss.iric@nhs.net)\n\n[Health Facilities Scotland - Incident Reporting and Investigation Centre](http://www.hfs.scot.nhs.uk/online-services/incident-reporting-and-investigation-centre-iric/) (external link).\n\n## Wales\n\nEnquiries in Wales should be addressed to:\n\nDr Sara Hayes  \nSenior Medical Officer  \nMedical Device Alerts  \nWelsh Assembly Government  \nCathays Park  \nCardiff  \nCF10 3NQ\n\nTel: 029 2082 3922\n\nEmail: [Haz-Aic@wales.gsi.gov.uk](mailto:Haz-Aic@wales.gsi.gov.uk)\n", 
  "raw_html": "<div id=\"inner_tab_content\">\r\n<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t\t\t\t\t\t\t\t\r\n<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t\t\t\t\t\t\t\t\r\n<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t\t\t\t\t\t\t\t\r\n<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t\t\t\t\t\t\t\t\r\n<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t\t\t\t\t\t\t\r\n<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t\t\t\t\t\t\t\r\n<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t\t\t\t\t\t\t\r\n<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t\t\t\t\t\t\t\r\n<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t\t\t\t\t\t\t\r\n<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t<h2 class=\"sw\">Device</h2><div class=\"content_section active_content_section\" id=\"Device\">\r\n\t\t\t\t\t\t\t\t<p><span>Novabel&#174; dermal filler.</span></p><p><span>Manufactured by Merz Pharmaceuticals GmbH.</span></p><p><span>1x1 ml, Art.-Nr. 40800 and 2x1ml, Art.-Nr. 49021.</span></p><p><span>All batches.</span></p><p>Novabel<font class=\"super\">&#174;</font> is a colourless dermal filler composed of cross-linked alginate. It is supplied in a prefilled, 1 ml, single-use syringe with two sterile 30G &#189; needles.</p>\r\n\t\t\t\t\t\t\t</div>\r\n<h2 class=\"sw\">Problem</h2><div class=\"content_section\" id=\"Problem\">\r\n\t\t\t\t\t\t\t\t<p><span>Use of Novabel<font class=\"super\">&#174;</font> dermal filler may cause adverse reactions.</span></p><p>Merz Pharmaceuticals GmbH issued a <a href=\"http://www.mhra.gov.uk/home/ssLINK/CON088238\">Field Safety Notice</a> (dated 23 July 2010), advising practitioners to stop using Novabel&#174;.</p><p>The manufacturer has received reports of adverse reactions to the filler including redness, bruising, pain, swelling and histologically confirmed granuloma. They have also received reports of nodules and indurations in the infra-orbital area.</p>\r\n\t\t\t\t\t\t\t</div>\r\n<h2 class=\"sw\">Action</h2><div class=\"content_section\" id=\"Action\">\r\n\t\t\t\t\t\t\t\t<ul>\r\n\t\t\t\t<li><span>Do not use Novabel<font class=\"super\">&#174;</font> dermal filler.</span></li>\r\n\t\t\t\t<li><span>Return all unused product to Merz Pharma UK Ltd.</span></li>\r\n\t\t\t\t<li><span>Monitor patients who have received Novabel<font class=\"super\">&#174;</font> and in particular those who exhibit symptoms linked to the use of Novabel<font class=\"super\">&#174;</font>.</span></li></ul><p>&#160;</p><ul>\r\n\t\t\t\t<li>If you administer Novabel<font class=\"super\">&#174;</font>:</li>\r\n\t\t\t\t<li style=\"LIST-STYLE-TYPE: none\">\r\n\t\t\t\t\t<ul>\r\n\t\t\t\t\t\t<li>cease use of the product</li>\r\n\t\t\t\t\t\t<li>return unused syringes to Merz Pharma UK Ltd.</li>\r\n\t\t\t\t\t\t<li>following application, patients should have been advised to return and seek treatment in case of progressive adverse reactions including redness, bruising, pain, swelling, nodules, indurations and granuloma</li>\r\n\t\t\t\t\t\t<li>follow up patients who exhibit residual adverse symptoms (described above) three months after application</li>\r\n\t\t\t\t\t\t<li>where symptoms persist, consider referring patients to a plastic surgeon for further treatment.</li>\r\n\t\t\t\t\t</ul>\r\n\t\t\t\t</li></ul><p>&#160;</p><ul>\r\n\t\t\t\t<li>If you are a plastic surgeon:</li>\r\n\t\t\t\t<li style=\"LIST-STYLE-TYPE: none\">\r\n\t\t\t\t\t<ul>\r\n\t\t\t\t\t\t<li>if a patient presents with symptoms linked to Novabel<font class=\"super\">&#174;</font> use, consider the need to treat with minocycline or injectable steroids.</li>\r\n\t\t\t\t\t</ul>\r\n\t\t\t\t</li></ul>\r\n\t\t\t\t\t\t\t</div>\r\n<h2 class=\"sw\">Distribution</h2><div class=\"content_section\" id=\"Distribution\">\r\n\t\t\t\t\t\t\t\t<p>This MDA has been distributed to:</p><ul>\r\n\t\t\t\t<li>NHS trusts in England (Chief Executives)</li>\r\n\t\t\t\t<li>HSC trusts in Northern Ireland (Chief Executives)</li>\r\n\t\t\t\t<li>NHS boards in Scotland (Chief Executives)</li>\r\n\t\t\t\t<li>NHS boards and trusts in Wales (Chief Executives)</li>\r\n\t\t\t\t<li>Primary care trusts in England (Chief Executives)</li></ul><p><font class=\"h3\">Onward distribution</font><br>Please bring this notice to the attention of all who need to know or be aware of it. This may include distribution by:</p><p><font class=\"h4\">Trusts to:<br></font> CAS and SABS (NI) liaison officers for onward distribution to all relevant staff including:</p><ul>\r\n\t\t\t\t<li>Clinical governance leads</li>\r\n\t\t\t\t<li>Day surgery units</li>\r\n\t\t\t\t<li>Dental departments</li>\r\n\t\t\t\t<li>Dental nurses</li>\r\n\t\t\t\t<li>Dentists</li>\r\n\t\t\t\t<li>General surgical units, directors of</li>\r\n\t\t\t\t<li>Health and safety managers</li>\r\n\t\t\t\t<li>Medical directors</li>\r\n\t\t\t\t<li>Nursing executive directors</li>\r\n\t\t\t\t<li>Ophthalmic nurses</li>\r\n\t\t\t\t<li>Ophthalmologists</li>\r\n\t\t\t\t<li>Ophthalmology departments</li>\r\n\t\t\t\t<li>Ophthalmology, directors of</li>\r\n\t\t\t\t<li>Outpatient clinics</li>\r\n\t\t\t\t<li>Outpatient theatre managers</li>\r\n\t\t\t\t<li>Outpatient theatre nurses</li>\r\n\t\t\t\t<li>Pharmacists</li>\r\n\t\t\t\t<li>Purchasing managers</li>\r\n\t\t\t\t<li>Supplies managers</li></ul><p><font class=\"h4\">Care Quality Commission (CQC) (England only) to:</font><br>The MHRA considers this information to be important to:</p><ul>\r\n\t\t\t\t<li>Clinics</li>\r\n\t\t\t\t<li>Hospitals in the independent sector</li>\r\n\t\t\t\t<li>Independent treatment centres</li>\r\n\t\t\t\t<li>Nursing agencies</li>\r\n\t\t\t\t<li>Private medical practitioners</li></ul><p><font class=\"h4\">Health Protection Agency to:<br></font> Directors for onward distribution to:</p><ul>\r\n\t\t\t\t<li>Divisional directors</li>\r\n\t\t\t\t<li>Heads of department</li>\r\n\t\t\t\t<li>Heads of health, safety and quality</li>\r\n\t\t\t\t<li>Health protection nurses</li>\r\n\t\t\t\t<li>Risk manager</li>\r\n\t\t\t\t<li>Safety officers</li></ul><p><font class=\"h4\">Primary care trusts to:</font><br>CAS liaison officers for onward distribution to all relevant staff including:</p><ul>\r\n\t\t\t\t<li>Community dental practices</li>\r\n\t\t\t\t<li>Community hospitals</li>\r\n\t\t\t\t<li>Community nurses</li>\r\n\t\t\t\t<li>Community pharmacists</li>\r\n\t\t\t\t<li>Directors of public health</li>\r\n\t\t\t\t<li>General dental practitioners</li>\r\n\t\t\t\t<li>General practitioners</li>\r\n\t\t\t\t<li>NHS walk-in centres</li>\r\n\t\t\t\t<li>Practice nurses</li></ul>\r\n\t\t\t\t\t\t\t</div>\r\n<h2 class=\"sw\">Manufacturer Contact</h2><div class=\"content_section\" id=\"Manufacturer Contact\">\r\n\t\t\t\t\t\t\t\t<p>Medical Information Department<br>Merz Pharma UK Ltd<br>260 Centennial Park<br>Elstree Hill South<br>Elstree<br>Herts<br>WD6 3SR</p><p>Tel: 020 8236 0000<br>Fax: 020 8236 3501</p><p>Email: <a href=\"mailto:medical.information@merz.com\">medical.information@merz.com</a></p>\r\n\t\t\t\t\t\t\t</div>\r\n<h2 class=\"sw\">Feedback</h2><div class=\"content_section\" id=\"Feedback\">\r\n\t\t\t\t\t\t\t\tIf you have any comments or feedback on this Medical Device Alert, please email us at: <a href=\"mailto:dts@mhra.gsi.gov.uk\">dts@mhra.gsi.gov.uk</a>\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t<h2 class=\"sw\">England</h2><div class=\"content_section\" id=\"England\">\r\n\t\t\t\t\t\t\t\t\t<p>If you are in England, please send enquiries about this notice to the MHRA, quoting reference number <span>MDA/2010/064</span> or <span>2010/007/023/081/016</span>.</p><p><font class=\"h4\">Technical aspects</font><br>Miss Feza Haque or Mr Ian Smith<br>Medicines&#160;and Healthcare products Regulatory Agency<br>Market Towers<br>1 Nine Elms Lane<br>London<br>SW8 5NQ</p><p>Tel: 020 7084 3066 / 3306<font face=\"ArialMT\" size=\"3\"><font face=\"ArialMT\" size=\"3\"><br></font></font>Fax: 020 7084 3106</p><p>Email: <a href=\"mailto:feza.haque@mhra.gsi.gov.uk\">feza.haque@mhra.gsi.gov.uk</a>&#160;and&#160;<a href=\"mailto:ian.smith@mhra.gsi.gov.uk\">ian.smith@mhra.gsi.gov.uk</a>&#160;</p><p><font class=\"h4\">Clinical aspects<br></font>Dr Nicola Lennard<br>Medicines&#160;and Healthcare products Regulatory Agency<br>Market Towers<br>1 Nine Elms Lane<br>London<br>SW8 5NQ</p><p>Tel: 020 7084 3126<br>Fax: 020 7084 3111</p><p>Email: <a href=\"mailto:nicola.lennard@mhra.gsi.gov.uk\">nicola.lennard@mhra.gsi.gov.uk</a>&#160;</p><p><font class=\"h3\">How to report adverse incidents<br></font>Please report via our website: <a href=\"http://www.mhra.gov.uk/Safetyinformation/Reportingsafetyproblems/index.htm\">Reporting adverse incidents involving medical devices</a>.<br>Further information about CAS can be found on the <a href=\"https://www.cas.dh.gov.uk/Home.aspx\" target=\"_blank\">Central Alerting System website</a> (external link).</p>\r\n\t\t\t\t\t\t\t\t</div>\r\n<h2 class=\"sw\">Northern Ireland</h2><div class=\"content_section\" id=\"Northern Ireland\">\r\n\t\t\t\t\t\t\t\t\t<p>Alerts in Northern Ireland will continue to be distributed via the NI SABS system.</p><p>Enquiries and adverse incident reports in Northern Ireland should be addressed to:<br>Northern Ireland Adverse Incident Centre<br>Health Estates Investment Group<br>Room 17<br>Annex 6<br>Castle Buildings<br>Stormont Estate<br>Dundonald<br>BT4 3SQ</p><p>Tel: 02890 523 704<br>Fax: 02890 523 900</p><p>Email: <a href=\"mailto:NIAIC@dhsspsni.gov.uk\">NIAIC@dhsspsni.gov.uk</a></p><p><a href=\"http://www.dhsspsni.gov.uk/index/hea/niaic.htm\" target=\"_blank\">Northern Ireland Adverse Incident Centre (NIAIC)</a> (external link)</p><p><font class=\"h3\">How to report adverse incidents in Northern Ireland</font><br>Please report directly to NIAIC, further information can be found on the <a href=\"http://www.dhsspsni.gov.uk/niaic\" target=\"_blank\">NIAIC website</a> (external link).<br>Further information about SABS can be found on the <a href=\"http://sabs.dhsspsni.gov.uk/NISABS/default.aspx?CATID=3\" target=\"_blank\">SABS website</a> (external link).</p>\r\n\t\t\t\t\t\t\t\t</div>\r\n<h2 class=\"sw\">Scotland</h2><div class=\"content_section\" id=\"Scotland\">\r\n\t\t\t\t\t\t\t\t\t<p>Enquiries and adverse incident reports in Scotland should be addressed to:</p><p>Incident Reporting and Investigation Centre<br>Health Facilities Scotland<br>NHS National Services Scotland<br>Gyle Square<br>1 South Gyle Crescent<br>Edinburgh<br>EH12 9EB</p><p>Tel: 0131 275 7575<br>Fax: 0131 314 0722</p><p>Email: <a href=\"mailto:nss.iric@nhs.net\">nss.iric@nhs.net</a></p><p><a href=\"http://www.hfs.scot.nhs.uk/online-services/incident-reporting-and-investigation-centre-iric/\" target=\"_blank\">Health Facilities Scotland - Incident Reporting and Investigation Centre</a> (external link).</p>\r\n\t\t\t\t\t\t\t\t</div>\r\n<h2 class=\"sw\">Wales</h2><div class=\"content_section\" id=\"Wales\">\r\n\t\t\t\t\t\t\t\t\t<p>Enquiries in Wales should be addressed to:</p><p>Dr Sara Hayes<br>Senior Medical Officer<br>Medical Device Alerts<br>Welsh Assembly Government<br>Cathays Park<br>Cardiff<br>CF10 3NQ</p><p>Tel: 029 2082 3922</p><p>Email: <a href=\"mailto:Haz-Aic@wales.gsi.gov.uk\">Haz-Aic@wales.gsi.gov.uk</a></p>\r\n\t\t\t\t\t\t\t\t</div>\r\n</div>\r\n\t\t\t", 
  "title": "Medical Device Alert: Novabel\u00ae dermal filler manufactured by Merz Pharmaceuticals GmbH (MDA/2010/064)", 
  "alert_type": [
    "devices"
  ], 
  "medical_specialism": []
}